Kim Chang Seong, Kim Min Jee, Kang Yong Un, Choi Joon Seok, Bae Eun Hui, Ma Seong Kwon, Ahn Young-Keun, Jeong Myung Ho, Kim Young Jo, Cho Myeong Chan, Kim Chong Jin, Kim Soo Wan
Department of Internal Medicine, Chonnam National University Medical School.
Int Heart J. 2013;54(5):304-10. doi: 10.1536/ihj.54.304.
The clinical course and medical treatment of patients with congestive heart failure (CHF) complicating acute myocardial infarction (AMI) are not well established, especially in patients with concomitant renal dysfunction. We performed a retrospective analysis of the prospective Korean Acute Myocardial Infarction Registry to assess the medical treatments and clinical outcomes of patients with CHF (Killip classes II or III) complicated by AMI, in the presence or absence of renal dysfunction. Of 13,498 patients with AMI, 2769 (20.5%) had CHF on admission. Compared to CHF patients with preserved renal function, in-hospital mortality and major adverse cardiac events were increased both at 1 month and at 1 year after discharge in patients with renal dysfunction (1154; 41.7%). Postdischarge use of aspirin, betablockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers and statins significantly reduced the 1-year mortality rate for CHF patients with renal dysfunction; such reduction was not observed for those without renal dysfunction, except in the case of aspirin. Patients with CHF complicating AMI, which is accompanied by renal dysfunction, are at higher risk for adverse cardiovascular outcomes than patients without renal dysfunction. However, they receive fewer medications proven to reduce mortality rates.
充血性心力衰竭(CHF)合并急性心肌梗死(AMI)患者的临床病程及药物治疗尚未完全明确,尤其是在伴有肾功能不全的患者中。我们对韩国急性心肌梗死前瞻性注册研究进行了回顾性分析,以评估合并或未合并肾功能不全的AMI合并CHF(Killip分级II或III级)患者的药物治疗及临床结局。在13498例AMI患者中,2769例(20.5%)入院时患有CHF。与肾功能正常的CHF患者相比,肾功能不全患者(1154例;41.7%)出院后1个月及1年的院内死亡率和主要不良心脏事件均有所增加。出院后使用阿司匹林、β受体阻滞剂、钙通道阻滞剂、血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂及他汀类药物可显著降低肾功能不全CHF患者的1年死亡率;除阿司匹林外,肾功能正常的患者未观察到此类死亡率降低情况。与肾功能正常的患者相比,AMI合并CHF且伴有肾功能不全的患者发生不良心血管结局的风险更高。然而,他们接受的经证实可降低死亡率的药物较少。